Vertex Pharmaceuticals Inc (VRTX)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	-232,900	-270,400	-348,600	4,192,500	3,832,000	3,877,000	3,965,600	4,045,500	4,307,400	4,151,600	4,079,400	2,935,200	2,782,100	2,650,192	2,267,933	3,023,866	2,856,290	2,661,963	2,089,055	1,640,982
Revenue (ttm)	US$ in thousands	10,984,000	10,582,900	10,283,600	10,120,000	9,803,200	9,596,700	9,444,700	9,144,300	8,863,500	8,628,770	8,277,080	7,873,370	7,499,400	7,066,960	6,622,470	6,355,190	6,147,530	5,935,020	5,347,582	4,763,428
Operating profit margin		-2.12%	-2.56%	-3.39%	41.43%	39.09%	40.40%	41.99%	44.24%	48.60%	48.11%	49.29%	37.28%	37.10%	37.50%	34.25%	47.58%	46.46%	44.85%	39.07%	34.45%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-232,900K ÷ $10,984,000K
= -2.12%

The operating profit margin of Vertex Pharmaceuticals Inc has shown fluctuations over the past few quarters. It started at a solid 34.45% in March 2020 and demonstrated a positive trend, reaching a peak of 49.29% in June 2022. However, a significant decline was observed in the subsequent quarters, dropping to -3.39% in June 2024. This negative trend continued as the operating profit margin remained in the negative territory at -2.56% in September 2024 and slightly improved to -2.12% by December 2024.

Overall, the operating profit margin of Vertex Pharmaceuticals Inc has seen both highs and lows during the period under consideration, indicating fluctuations in the company's profitability and efficiency in managing its operating costs. Further analysis and monitoring of financial performance are recommended to understand the factors contributing to these fluctuations and to make informed decisions regarding the company's operations and strategy.